目的 探究蓝芩口服液联合注射用哌拉西林舒巴坦对社区获得性肺炎患儿的治疗效果及其对肺功能、炎症因子的影响。方法 选取2023年4月—2024年3月皖西卫生职业学院附属医院收治的87例社区获得性肺炎患儿，以随机数字表法分为对照组44例、治疗组43例。对照组静脉滴注注射用哌拉西林钠舒巴坦钠，将注射用哌拉西林钠舒巴坦钠与100 mL生理盐水混合均匀，剂量为0.20～0.25 g/(kg∙d)，2次/d。治疗组口服蓝芩口服液，6岁≤患儿年龄＜7岁，5 mL/次；7岁≤患儿年龄≤12岁，10 mL/次，3次/d。治疗组注射用哌拉西林钠舒巴坦钠用法用量与对照组一致。两组均连续治疗5 d。观察两组患儿的治疗效果和临床症状消失时间，比较两组患者的肺功能指标和血清炎症指标。结果 治疗后，治疗组总有效率是95.35%，显著高于对照组的79.55%，具有统计学差异（P＜0.05）。治疗组体温复常、喘息消失时间、咳嗽消失时间、肺部啰音消失时间短于对照组，具有统计学差异（P＜0.05）。治疗后，两组潮气量（VT）、最大呼气中段流量（MMFE）、峰流速（PEF）水平较同组治疗前显著升高（P＜0.05）；治疗后，治疗组VT、MMFE、PEF水平较对照组升高幅度更为明显，有统计学差异（P＜0.05）。治疗后，两组C反应蛋白（CRP）、降钙素原（PCT）、白细胞介素-6（IL-6）水平均明显下降（P＜0.05）；治疗后，治疗组CRP、PCT、IL-6水平较对照组下降幅度更为明显，具有统计学差异（P＜0.05）。结论 社区获得性肺炎患儿使用蓝芩口服液联合哌拉西林舒巴坦治疗临床症状快速恢复，可有效缩短病程，改善患儿肺功能和炎症反应。

Objective To explore the therapeutic effect of Lanqin Oral Liquid combined with Piperacillin Sodium and Sulbactam Sodium for injection on children with community-acquired pneumonia and its influence on lung function and inflammatory factors. Methods A total of 87 children with community-acquired pneumonia (CAP) admitted to The Affiliated Hospital of Wanxi Health Vocational College from April 2023 to March 2024 were enrolled. They were divided into the control group (44 cases) and the treatment group (43 cases) using a random number table method. Children in control group were iv administered with Piperacillin Sodium and Sulbactam Sodium for injection, 0.20 — 0.25 g/(kg∙d), twice daily. Children in treatment group were po administered with Lanqin Oral Liquid, 5 mL each time, for children aged 6 to 7 years old. For children aged 7 to 12 years old, 10 mL each time, 3 times daily. The dosage and administration of Piperacillin Sodium and Sulbactam Sodium for injection in treatment group were the same as those in control group. Both groups were treated continuously for 5 d. The therapeutic effects and the disappearance time of clinical symptoms of two groups of children were observed, and the pulmonary function indicators and serum inflammatory indicators of two groups were compared. Results After treatment, the total effective rate of the treatment group was 95.35%, significantly higher than that of the control group (79.55%), with a statistically significant difference (P < 0.05). The time to fever resolution, time to relief of wheezing, time to cough disappearance, and time to disappearance of pulmonary rales in the treatment group were all significantly shorter than those in the control group, with statistically significant differences (P < 0.05). After treatment, the levels of tidal volume (VT), maximum mid-expiratory flow (MMFE), and peak expiratory flow (PEF) in both groups were significantly higher than those before treatment in the same group (P < 0.05); additionally, the increases in VT, MMFE, and PEF levels in the treatment group were more pronounced compared with the control group after treatment, and the differences were statistically significant (P < 0.05). After treatment, the levels of C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) in both groups were significantly lower than those before treatment in the same group (P < 0.05); moreover, the decreases in CRP, PCT, and IL-6 levels in the treatment group were more notable than those in the control group after treatment, with statistically significant differences (P < 0.05). Conclusion Children with community-acquired pneumonia who are treated with Lanqin Oral Liquid combined with piperacillin sulbactam can recover their clinical symptoms rapidly, effectively shorten the course of the disease, and improve their lung function and inflammatory response.

R974;R985

安徽省卫生健康科研项目（AHWJ2023A10087)